GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
US3578687A
(en)
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
US3819561A
(en)
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
JPS5313608B2
(es)
|
1972-06-16 |
1978-05-11 |
|
|
JPS5318013B2
(es)
|
1973-03-19 |
1978-06-13 |
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
CN1138541C
(zh)
|
1994-08-08 |
2004-02-18 |
德彪药品股份有限公司 |
一种药学上稳定的奥沙利铂制剂
|
CA2202503C
(en)
|
1994-10-13 |
2008-07-15 |
Antonio Ferrante |
Modified polyunsaturated fatty acids
|
US5919816A
(en)
|
1994-11-14 |
1999-07-06 |
Bionumerik Pharmaceuticals, Inc. |
Formulations and methods of reducing toxicity of antineoplastic agents
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
WO1999022719A1
(fr)
|
1997-10-30 |
1999-05-14 |
Morishita Jintan Co., Ltd. |
Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication
|
ID25871A
(id)
|
1997-11-12 |
2000-11-09 |
Bayer Ag |
Imidazotriazinon tersubstitusi-2-fenil
|
US7795246B2
(en)
|
1998-08-06 |
2010-09-14 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
AU5565599A
(en)
|
1998-08-14 |
2000-03-06 |
Dante J. Marciani |
Chemically modified saponins and the use thereof as adjuvants
|
SK10322001A3
(sk)
|
1999-01-20 |
2002-07-02 |
Arzneimittelwerk Dresden Gmbh |
Spôsob prípravy imidazo [1,5-a]pyrido[3,2-e]pyrazínov, farmaceutické prostriedky obsahujúce takéto zlúčeniny a spôsob výroby farmaceutického prostriedku
|
IL145712A0
(en)
|
1999-04-01 |
2002-07-25 |
Esperion Therapeutics Inc |
Ether compounds, compositions, and uses thereof
|
WO2001006983A2
(en)
|
1999-07-22 |
2001-02-01 |
Incell Corporation, Llc |
Fatty acids to minimize cancer therapy side effects
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
AUPQ291499A0
(en)
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
IL139455A0
(en)
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
US20010037598A1
(en)
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
WO2001060778A2
(en)
|
2000-02-16 |
2001-08-23 |
The Brigham And Women's Hospital, Inc. |
Aspirin-triggered lipid mediators
|
AR032318A1
(es)
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
AR030416A1
(es)
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
AR034120A1
(es)
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
CA2412232C
(en)
|
2000-06-28 |
2010-03-30 |
Zambon Group S.P.A. |
Process for the preparation of nitroalkenes
|
AR031129A1
(es)
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
ATE365037T1
(de)
|
2001-03-02 |
2007-07-15 |
Debiopharm Sa |
Verwendung eines eine oxaliplatinlösung beinhaltenden fläschchens
|
DE60223670T2
(de)
|
2001-04-18 |
2008-03-06 |
Prometic Biosciences Inc., Mont-Royal |
Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
WO2002102364A1
(fr)
|
2001-06-18 |
2002-12-27 |
Yamada, Sachiko |
Preparations medicamenteuses agonistes ppar$g(g)
|
CN1571672A
(zh)
|
2001-08-17 |
2005-01-26 |
匹兹堡大学 |
给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
PL370599A1
(en)
|
2001-11-02 |
2005-05-30 |
Pfizer Products Inc. |
Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
|
HN2002000317A
(es)
|
2001-11-02 |
2003-05-21 |
Pfizer |
Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
|
US20030166716A1
(en)
|
2001-11-06 |
2003-09-04 |
Serhan Charles N. |
Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
|
GB2388111A
(en)
|
2002-05-01 |
2003-11-05 |
Bayer Ag |
Novel imidazotriazinone compounds
|
US6684626B1
(en)
|
2002-07-30 |
2004-02-03 |
General Electric Company |
Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
CA2875522A1
(en)
|
2002-08-20 |
2004-03-04 |
Philera New Zealand Limited |
Dosage forms and related therapies
|
AU2003272738B2
(en)
|
2002-09-27 |
2010-04-01 |
Martek Biosciences Corporation |
Docosahexaenoic acid for improved glycemic control
|
WO2004037311A2
(en)
|
2002-10-21 |
2004-05-06 |
Kensey Nash Corporation |
Device and methods for sequential, regional delivery of multiple cytotoxic agents
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
US7935365B2
(en)
|
2003-10-22 |
2011-05-03 |
Enzymotec, Ltd. |
Glycerophospholipids for the improvement of cognitive functions
|
CA2543522A1
(en)
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
WO2005073164A1
(en)
|
2004-01-30 |
2005-08-11 |
Peplin Biolipids Pty Ltd |
Therapeutic and carrier molecules
|
CA2563533C
(en)
|
2004-04-15 |
2013-10-01 |
Shmuel A. Ben-Sasson |
Compositions capable of facilitating penetration across a biological barrier
|
US7776916B2
(en)
|
2004-04-28 |
2010-08-17 |
The Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
NZ553263A
(en)
|
2004-07-19 |
2010-06-25 |
Biocon Ltd |
Insulin-oligomer conjugates, formulations and uses thereof
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
EP1772149A1
(en)
|
2004-07-27 |
2007-04-11 |
Kowa Company. Ltd. |
Drug for prevention or treatment of diabetes
|
EP1824809A4
(en)
|
2004-11-19 |
2010-03-03 |
Martek Biosciences Corp |
OXYLIPINES OF LONG-CHAIN, MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
WO2006058250A2
(en)
|
2004-11-24 |
2006-06-01 |
Spi Pharma, Inc. |
Orally disintegrating compositions
|
AU2011202664B2
(en)
|
2004-12-08 |
2012-04-05 |
Cedars-Sinai Medical Center |
Methods for diagnosis and treatment of Crohn's disease
|
US20070032420A1
(en)
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
EP1928237A4
(en)
|
2005-09-02 |
2011-03-09 |
Abbott Lab |
NEW HETEROCYCLES BASED ON IMIDAZO
|
GB0522569D0
(en)
|
2005-11-04 |
2005-12-14 |
Univ Bath |
Biocompatible drug delivery device
|
TW200815436A
(en)
|
2006-05-30 |
2008-04-01 |
Elbion Ag |
4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US20090264483A1
(en)
|
2006-07-14 |
2009-10-22 |
Cedars-Sinai Medical Center |
METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
|
CN101528218A
(zh)
|
2006-07-19 |
2009-09-09 |
雷索维克斯药品公司 |
治疗粘膜炎的组合物和方法
|
WO2008029589A1
(fr)
|
2006-09-08 |
2008-03-13 |
Tokuyama Corporation |
Procédé et matériel servant à produire un nitrure d'un élément du groupe iii
|
CA2672591A1
(en)
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
Treating agent of uropathy
|
KR101555384B1
(ko)
|
2006-12-13 |
2015-09-23 |
아스카 세이야쿠 가부시키가이샤 |
퀴녹살린 유도체
|
EP2120920A4
(en)
|
2007-02-20 |
2011-06-15 |
Martek Biosciences Corp |
OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
|
SI2152712T1
(sl)
|
2007-05-11 |
2012-03-30 |
Pfizer |
Amino heterociklične spojine
|
DE102007032349A1
(de)
|
2007-07-11 |
2009-01-15 |
Bayer Healthcare Ag |
Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
|
DK2180787T3
(da)
|
2007-08-01 |
2014-02-03 |
Univ Pittsburgh |
Nitrooliesyremodulering af type ii-diabetes
|
AU2008301895A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Oxylipin compounds for treating autoimmune diseases
|
ES2638463T3
(es)
*
|
2008-03-10 |
2017-10-20 |
Takeda Pharmaceutical Company Limited |
Cristal de compuesto de bencimidazol
|
EP2271929B1
(en)
|
2008-04-18 |
2015-11-25 |
The University of Utah Research Foundation |
Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
|
WO2009134383A2
(en)
|
2008-05-01 |
2009-11-05 |
Complexa Inc. |
Vinyl substituted fatty acids
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
WO2009155439A2
(en)
|
2008-06-19 |
2009-12-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
WO2010012777A1
(en)
|
2008-07-29 |
2010-02-04 |
Nerviano Medical Sciences S.R.L. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
US9139554B2
(en)
|
2008-10-09 |
2015-09-22 |
Tekmira Pharmaceuticals Corporation |
Amino lipids and methods for the delivery of nucleic acids
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
AU2009334476B2
(en)
|
2008-12-31 |
2013-08-29 |
Nitromega Corp. |
Nutraceuticals containing nitro fatty acids
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基-雜環化合物
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
US20110082147A1
(en)
|
2009-07-24 |
2011-04-07 |
Concert Pharmaceuticals, Inc. |
Substituted imidazotriazines
|
JP2013500275A
(ja)
|
2009-07-29 |
2013-01-07 |
フェノメノーム ディスカバリーズ インク |
ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用
|
EP2459189A4
(en)
|
2009-07-31 |
2013-01-16 |
Univ Pittsburgh |
FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
|
US9260432B2
(en)
|
2009-09-02 |
2016-02-16 |
Concert Pharmaceuticals, Inc. |
Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
|
WO2011030351A2
(en)
|
2009-09-03 |
2011-03-17 |
Rubicon Research Private Limited |
Taste - masked pharmaceutical compositions
|
EP2483233A4
(en)
|
2009-10-02 |
2013-08-14 |
Complexa Inc |
HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
|
CN102822152A
(zh)
|
2009-11-09 |
2012-12-12 |
诺瓦德克斯制药股份有限公司 |
新颖的1,3-噁唑烷化合物及其作为肾素抑制剂的用途
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
WO2011113507A2
(en)
|
2010-03-15 |
2011-09-22 |
Ulrich Dietz |
Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
|
JP2013526865A
(ja)
|
2010-05-13 |
2013-06-27 |
ニトロメガ コーポレーション |
ニトロ脂肪酸、神経保護および/または認識減退の抑制
|
JP2013534930A
(ja)
|
2010-06-28 |
2013-09-09 |
コンプレクサ,インコーポレイテッド |
糖尿病を治療するための多成分調剤
|
EP3181566A1
(en)
|
2010-09-20 |
2017-06-21 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
CN103930423B
(zh)
|
2011-10-07 |
2015-09-16 |
卫材Rd管理有限公司 |
吡唑并喹啉衍生物
|
CN106905324B
(zh)
|
2011-10-10 |
2018-09-25 |
H.隆德贝克有限公司 |
具有咪唑并吡嗪酮骨架的pde9抑制剂
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
DE102012008730A1
(de)
|
2011-12-02 |
2013-06-06 |
Dr. Budz GmbH |
Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
|
CN104093720B
(zh)
|
2012-01-26 |
2017-04-12 |
H.隆德贝克有限公司 |
具有咪唑并三嗪酮骨架的pde9抑制剂
|
CN104136423B
(zh)
|
2012-02-01 |
2019-03-08 |
希望之城 |
核糖核苷酸还原酶抑制剂和使用方法
|
CA2863765A1
(en)
|
2012-02-03 |
2013-08-08 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Fatty acids as anti-inflammatory agents
|
US10435367B2
(en)
|
2013-03-14 |
2019-10-08 |
City Of Hope |
Indirubin derivatives, and uses thereof
|
WO2013142269A1
(en)
|
2012-03-19 |
2013-09-26 |
Envivo Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
US10058688B2
(en)
|
2012-05-09 |
2018-08-28 |
Massachusetts Institute Of Technology |
Medicament, method, and drug delivery device for treatment of ovarian cancer
|
WO2014036555A1
(en)
|
2012-08-31 |
2014-03-06 |
Taris Biomedical, Inc. |
Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
|
US20140271844A1
(en)
|
2013-03-15 |
2014-09-18 |
Nitromega Corp. |
Compositions containing nitro fatty acids
|
EP2983730B1
(en)
|
2013-04-10 |
2019-10-16 |
Massachusetts Institute of Technology |
Local drug delivery devices and methods for treating cancer
|
CN105339006A
(zh)
|
2013-05-10 |
2016-02-17 |
尼特罗米加公司 |
含有脂肪酸和亚硝酸盐的营养或膳食补充剂
|
US20150051283A1
(en)
|
2013-06-14 |
2015-02-19 |
Complexa, Inc. |
Composition and method for inhibition of pkng from mycobacterium tuberculosis
|
EP3033138A4
(en)
|
2013-08-12 |
2017-03-29 |
Nanomedical Systems Inc. |
Device and method for sustained release of low water solubility therapeutic agent in solubilizer
|
WO2015073527A1
(en)
|
2013-11-12 |
2015-05-21 |
Complexa, Inc. |
Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
|
WO2015185499A1
(en)
|
2014-06-06 |
2015-12-10 |
H. Lundbeck A/S |
Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
|
WO2016161285A1
(en)
|
2015-04-02 |
2016-10-06 |
Aobiome Llc |
Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
|
ES2971969T3
(es)
*
|
2015-07-07 |
2024-06-10 |
H Lundbeck As |
Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
|
KR20180098222A
(ko)
|
2015-10-02 |
2018-09-03 |
컴플렉사, 인코포레이티드 |
활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행
|
US9771366B2
(en)
|
2016-02-19 |
2017-09-26 |
Phoenix Molecular Design |
Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors
|
BR112019000005A2
(pt)
|
2016-07-06 |
2019-04-16 |
H. Lundbeck A/S |
inibidores de pde9 para o tratamento de doenças periféricas
|
US11370795B2
(en)
|
2017-05-26 |
2022-06-28 |
Imara Inc. |
Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
|
CN117843645A
(zh)
|
2018-05-25 |
2024-04-09 |
伊马拉公司 |
一种pde9抑制剂的一水合物和结晶形态
|
AU2019328299A1
(en)
|
2018-08-31 |
2021-04-22 |
Cardurion Pharmaceuticals, Inc. |
PDE9 inhibitors for treating sickle cell disease
|
JP2022527630A
(ja)
|
2019-04-05 |
2022-06-02 |
イマラ インク. |
鎌状赤血球症を治療するためのpde9阻害剤
|
EP3965768A1
(en)
|
2019-05-07 |
2022-03-16 |
Imara Inc. |
Pde9 inhibitors for treating thalassemia
|